RA
DXCM icon

Rise Advisors’s DexCom DXCM Stock Holding History

Rise Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-793
Closed -$53.4K – 493
2025
Q3 		$53.4K Sell
793
-7
-0.9% -$554 0.02% 240
2025
Q2 		$69.8K Buy
800
+20
+3% +$1.57K 0.03% 200
2025
Q1 		$53.3K Buy
780
+14
+2% +$1.14K 0.02% 217
2024
Q4 		$59.6K Sell
766
-27
-3% -$2K 0.03% 200
2024
Q3 		$53.2K Sell
793
-44
-5% -$3.61K 0.03% 227
2024
Q2 		$94.9K Hold
837
– – 0.05% 153
2024
Q1 		$116K Buy
837
+201
+32% +$25.3K 0.06% 134
2023
Q4 		$78.9K Sell
636
-24
-4% -$2.45K 0.06% 122
2023
Q3 		$61.6K Buy
660
+528
+400% +$59.5K 0.05% 124
2023
Q2 		$17K Sell
132
-60
-31% -$7.26K 0.01% 258
2023
Q1 		$22.3K Hold
192
– – 0.02% 238
2022
Q4 		$21.7K Hold
192
– – 0.02% 238
2022
Q3 		$15K Hold
192
– – 0.01% 281
2022
Q2 		$14K Hold
192
– – 0.01% 279
2022
Q1 		$25K Hold
192
– – 0.02% 218
2021
Q4 		$25.8K Buy
+192
New +$27.6K 0.02% 216

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Rise Advisors's DXCM Position: Q4 2025 in Review

Rise Advisors sold out of DexCom (DXCM) in Q4 2025, closing a stake of 793 shares — an estimated $53.4K sold.

Rise Advisors first reported a position in DXCM in Q4 2021 and held it in 16 quarters. The position peaked at $116K in Q1 2024. 922 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

  • Rise Advisors reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 793 DexCom shares in Q4 2025, an estimated $53.4K.
  • Rise Advisors first reported a position in DexCom in Q4 2021 and held it in 16 quarters.
  • Rise Advisors's DexCom position peaked at $116K in Q1 2024.
  • 922 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.